United Laboratories International Holdings Ltd
UNJ
Company Profile
Business description
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.
Contact
No. 6 Fuk Wang Street
Yuen Long Industrial Estate
New Territories
Hong Kong
HKGSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
15,000
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,073.98 | 45.70 | 0.57% |
| DAX 40 | 23,154.57 | 167.75 | 0.73% |
| Dow JONES (US) | 41,841.63 | 353.44 | 0.85% |
| FTSE 100 | 8,680.29 | 47.96 | 0.56% |
| HKSE | 24,667.98 | 522.41 | 2.16% |
| NASDAQ | 17,808.66 | 54.58 | 0.31% |
| Nikkei 225 | 37,868.96 | 472.44 | 1.26% |
| NZX 50 Index | 12,061.32 | 104.82 | -0.86% |
| S&P 500 | 5,675.12 | 36.18 | 0.64% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,428.77 | 2.64 | 0.08% |